Biomerica Stock Rises on FDA Approval
- Share via
NEWPORT BEACH — Biomerica Inc. shares rose Tuesday after the company said it received Food and Drug Administration approval to market a thyroid disease test.
The manufacturer of medical diagnostic products said it has started talks with several potential marketing partners for the product, which detects antibodies that are present in patients with several types of thyroid disease, the company said. Biomerica’s stock rose 62.5 cents a share to close at $2.375 in Tuesday’s trading on the Nasdaq market.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
